## MDT: Medtronic plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.5% below STRENGTH zone (4.0-10.0%); PEG 3.64 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($94.51)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. The Truth About Medtronic plc: Is This ‘Boring’ Stock Actually a Silent Flex?**
- Source: AD HOC NEWS | 20260105T080832 | Somewhat-Bullish | Relevance: 100%
- Medtronic plc is presented as a medical technology giant that, while not a "meme stock," is a significant player in healthcare. The article explores whether this "boring" stock is a valuable long-term investment, examining its business, market perception, and risks. It concludes that Medtronic is a stable, dividend-paying company suited for core portfolios rather than speculative, high-volatility trading.

**2. D.A. Davidson & CO. Has $20.33 Million Holdings in Medtronic PLC $MDT**
- Source: MarketBeat | 20260105T141625 | Bullish | Relevance: 100%
- D.A. Davidson & CO. has lowered its stake in Medtronic PLC (NYSE:MDT) by 9.9% in Q3, now holding 213,482 shares valued at $20.33 million. Medtronic exceeded Q3 earnings estimates with $1.36 EPS and $8.96 billion in revenue, forecasting FY26 EPS between $5.62 and $5.66. The company also announced a quarterly dividend of $0.71, translating to an annualized yield of approximately 3.0%.

**3. Asset Management One Co. Ltd. Has $56.11 Million Stake in Medtronic PLC $MDT**
- Source: MarketBeat | 20260104T095124 | Bullish | Relevance: 100%
- Asset Management One Co. Ltd. increased its holdings in Medtronic PLC (NYSE:MDT) by 2.4% in the third quarter, bringing its total stake to 589,186 shares valued at $56.11 million. Medtronic recently outperformed Q3 earnings estimates with an EPS of $1.36 and revenue of $8.96 billion, and announced a quarterly dividend of $0.71. The company holds a consensus "Moderate Buy" rating from analysts with an average target price of $109.94.

**4. Davis Capital Management Makes New $1.26 Million Investment in Medtronic PLC $MDT**
- Source: MarketBeat | 20260104T092324 | Bullish | Relevance: 100%
- Davis Capital Management has made a new investment of $1.26 million in Medtronic PLC, acquiring 13,201 shares during the third quarter. Medtronic (NYSE: MDT) has received a "Moderate Buy" consensus rating from analysts, with a price target of $109.94, and recently beat Q3 earnings and revenue estimates. The company reported EPS of $1.36 and revenue of $8.96 billion, and announced a quarterly dividend of $0.71 per share, reflecting an annualized yield of approximately 3.0%.

**5. Capital Advisors Inc. OK Raises Stake in Medtronic PLC $MDT**
- Source: MarketBeat | 20260104T092124 | Somewhat-Bullish | Relevance: 100%
- Capital Advisors Inc. OK increased its holdings in Medtronic PLC by 24.9% in Q3, now owning 590,228 shares valued at $56.21 million. Medtronic surpassed quarterly expectations with $1.36 EPS and $8.96 billion in revenue, setting a positive FY 2026 guidance. Analyst consensus for MDT is a "Moderate Buy" with an average price target of $109.94.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $107 | $110 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($0.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Valuation stretched: PEG 3.6x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.64 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $124.9B |
| Beta | 0.73 |
| 52W Range | $79.55 - $106.33 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.64 |
| Forward P/E | 15.9 |
| Current P/E | 17.2 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.1% to -0.5% (+2.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.5pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.8%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). RSI neutral at 47. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.54% (CS: 34) | Neutral |
| RSI_14 | 46.6 | Neutral |
| MACD Histogram | -0.31 | Bearish |
| vs SMA20 | 0.991x | Below |
| vs SMA50 | 1.000x | Below |
| vs SMA200 | 1.066x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $97.39
- **Stop Loss:** $94.51 (3.0% risk)
- **Target:** $100.27 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 299
- **Position Value:** $29,119.61
- **Portfolio %:** 29.12%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*